# US 2023/0056066 A1 · Plakophillin-2 gene therapy methods and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056066 A1
- Document ID: US20230056066A1
- Status: Published application
- Kind: A1
- Application number: 17/882,314
- Filed: 2022-08-05
- Published: 2023-02-23
- Earliest claimed: 2020-10-09
- Assignees: Tenaya Therapeutics, Inc.
- Applicants: Tenaya Therapeutics, Inc.
- Inventors: Zhihong Jane YANG; Jaclyn HO; Chris REID; Jin YANG
- Web page: https://patentgrep.com/patent/US20230056066A1

## CPC

- C12N 15/86: Viral vectors
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/47: from mammals
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0375: Animal model for cardiovascular diseases
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Provided herein are methods and compositions for plakophilin-2 gene therapy for treating heart diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) or arrhythmogenic cardiomyopathy (ACM).

## Claims

### Claim 1

A method for restoring desmosome structure and/or function in an individual in need thereof, the method comprising administering an adeno-associated virus (AAV) gene therapy vector comprising a nucleic acid encoding a plakophilin 2 (PKP2) polypeptide operatively linked to a promoter, wherein the AAV is selected from the group consisting of an AAV6, an AAV8, an AAV.rh74, and an AAV9, thereby restoring desmosome structure and/or function in the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein the AAV is an AAV9.

### Claim 3 (depends on 1)

The method of claim 1, wherein the individual has a heart disease or disorder.

### Claim 4 (depends on 3)

The method of claim 3, wherein the heart disease or disorder is arrhythmogenic right ventricular cardiomyopathy (ARVC) or arrhythmogenic cardiomyopathy (ACM).

### Claim 5 (depends on 1)

The method of claim 1, wherein the promoter is a cardiac specific promoter.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cardiac specific promoter is a PKP2 promoter, a troponin promoter, or an alpha-myosin heavy chain promoter.

### Claim 7 (depends on 1)

The method of claim 1, wherein the AAV gene therapy vector further comprises a 3′ element.

### Claim 8 (depends on 7)

The method of claim 7, wherein the 3′ element comprises a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE), a bovine growth hormone polyadenylation (bGH polyA) sequence, or a combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the AAV gene therapy vector further comprises a cardiac specific enhancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method reduces or prevents at least one of fibrofatty tissue replacement; myocardial atrophy; predominant right ventricular dilation; ventricular arrhythmias; sudden cardiac death; exercise-triggered cardiac events; right ventricular cardiomyopathy, dilation, or heart failure; left ventricular cardiomyopathy, dilation, or heart failure; atrial arrhythmias; syncope; palpitations; shortness of breath; or chest pain.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method reverses at least one of fibrofatty tissue replacement; myocardial atrophy; predominant right ventricular dilation; ventricular arrhythmias; sudden cardiac death; exercise-triggered cardiac events; right ventricular cardiomyopathy, dilation, or heart failure; left ventricular cardiomyopathy, dilation, or heart failure; atrial arrhythmias; syncope; palpitations; shortness of breath; or chest pain.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method restores expression of one or more genes having a direct or indirect effect on one or more symptoms of a heart disease or disorder.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more genes comprises one or more of Ryanodine Receptor 2 (Ryr2), Ankyrin-B (Ank2), Cacna1c (CaV1.2), triadin (Trdn), or calsequestrin-2 (Casq2).

### Claim 14 (depends on 1)

The method of claim 1, wherein the individual is identified as having at least one variation in a desmosome protein.

### Claim 15 (depends on 14)

The method of claim 14, wherein the desmosome protein is PKP2.

### Claim 16 (depends on 15)

The method of claim 15, wherein the variation comprises a deletion, an insertion, a single nucleotide variation, or a copy number variation.

### Claim 17 (depends on 1)

The method of claim 1, wherein the administering is intracardiac injection, intramyocardiac injection, endocardial injection, intracardiac catheterization, or systemic administration.

### Claim 18 (depends on 17)

The method of claim 17, wherein the administering is systemic administration.

### Claim 19 (depends on 1)

The method of claim 1, wherein the AAV gene therapy vector is administered in a composition comprising a pharmaceutically acceptable carrier or excipient.
